Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 1/2020

01-01-2020 | Pathology | Guidelines

EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma

Authors: Luca Giovanella, Giorgio Treglia, Ioannis Iakovou, Jasna Mihailovic, Frederik A. Verburg, Markus Luster

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 1/2020

Login to get access

Abstract

Background

Medullary thyroid carcinoma (MTC) is a malignant tumour derived from the para-follicular thyroid C cells. It may occur in sporadic or hereditary forms and surgery represent the primary cure.

Methods

Ultrasound examination and, in selected cases, cross-sectional anatomic imaging procedures, are adopted to stage the disease before primary surgery while different anatomic/morphologic and functional/molecular imaging procedures can be adopted in detecting persistent/recurrent disease. Positron emitting radiopharmaceuticals including fluorine-18 fluorodeoxyglucose (18F-FDG), fluorine-18 dihydroxyphenylalanine (18F-FDOPA) and somatostatin analogues labelled with gallium-68 (68Ga-SSA) tracks different metabolic pathways or receptor expression/functioning, and proved to be useful in detecting MTC recurrences/metastasis.

Conclusions

This practice guideline from the Thyroid Committee of the European Association of Nuclear Medicine (EANM), with involvement of external experts, provides recommendations based on updated literature’s evidences. The purpose of this practice guideline is to assist imaging specialists and clinicians in recommending, performing and interpreting the results of PET/CT with various radiopharmaceuticals in patients with MTC.
Literature
1.
Trimboli P, Giovanella L, Crescenzi A, Romanelli F, Valabrega S, Spriano G, et al. Medullary thyroid cancer diagnosis: an appraisal. Head Neck. 2014;36:1216–23.PubMedCrossRef
2.
Guyetant S, Rousselet MC, Durigon M, Chappard D, Franc B, Guerin O, et al. Sex-related C-cell hyperplasia in the normal human thyroid: a quantitative autopsy study. J Clin Endocrinol Metab. 1997;82:42–7.PubMedCrossRef
3.
Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 1993;363:458–60.PubMedCrossRef
4.
Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature. 1994;367:375–6.PubMedCrossRef
5.
Marsh DJ, Learoyd DL, Andrew SD, Krishnan L, Pojer R, Richardson AL, et al. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol. 1996;44:249–57.CrossRef
6.
Boichard A, Croux L, Al Ghuzlan A, Broutin S, Dupuy C, Leboulleux S, et al. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. J Clin Endocrinol Metab. 2012;97:E2031–5.PubMedPubMedCentralCrossRef
7.
Agrawal N, Jiao Y, Sausen M, Leary R, Bettegowda C, Roberts NJ, et al. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab. 2013;98:E364–9.PubMedCrossRef
8.
Leboulleux S, Baudin E, Travagli JP, Schlumberger M. Medullary thyroid carcinoma. Clin Endocrinol. 2004;61:299–310.CrossRef
9.
Machens A, Hinze R, Thomusch O, Dralle H. Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg. 2002;26:22–8.PubMedCrossRef
10.
Moley JF. Medullary thyroid carcinoma: management of lymph node metastases. J Natl Compr Cancer Netw. 2010;8:549–56.CrossRef
11.
Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC study group. Groupe d’etude des tumeurs a calcitonine. Clin Endocrinol. 1998;48:265–73.CrossRef
12.
Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25:567–610.PubMedPubMedCentralCrossRef
13.
Trimboli P, Seregni E, Treglia G, Alevizaki M, Giovanella L. Procalcitonin for detecting medullary thyroid carcinoma: a systematic review. Endocr Relat Cancer. 2015;22:R157–64.PubMedCrossRef
14.
Trimboli P, Giovanella L. Serum calcitonin negative medullary thyroid carcinoma: a systematic review of the literature. Clin Chem Lab Med. 2015;53:1507–14.PubMedCrossRef
15.
Trimboli P, Treglia G, Guidobaldi L, Romanelli F, Nigri G, Valabrega S, et al. Detection rate of FNA cytology in medullary thyroid carcinoma: a meta-analysis. Clin Endocrinol. 2015;82:280–5.CrossRef
16.
Trimboli P, Guidobaldi L, Bongiovanni M, Crescenzi A, Alevizaki M, Giovanella L. Use of fine-needle aspirate calcitonin to detect medullary thyroid carcinoma: a systematic review. Diagn Cytopathol. 2016;44:45–51.PubMedCrossRef
17.
Chernock RD, Hagemann IS. Molecular pathology of hereditary and sporadic medullary thyroid carcinomas. Am J Clin Pathol. 2015;143:768–77.PubMedCrossRef
18.
Khurana R, Agarwal A, Bajpai VK, Verma N, Sharma AK, Gupta RP, et al. Unraveling the amyloid associated with human medullary thyroid carcinoma. Endocrinology. 2004;145:5465–70.PubMedCrossRef
19.
Mendelsohn G, Wells SA Jr, Baylin SB. Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma. An immunohistochemical study in early, localized, and virulent disseminated stages of disease. Cancer. 1984;54:657–62.PubMedCrossRef
20.
Trimboli P, Giovanella L, Valabrega S, Andrioli M, Baldelli R, Cremonini N, et al. Ultrasound features of medullary thyroid carcinoma correlate with cancer aggressiveness: a retrospective multicenter study. J Exp Clin Cancer Res. 2014;33:87.PubMedPubMedCentralCrossRef
21.
22.
Rufini V, Castaldi P, Treglia G, Perotti G, Gross MD, Al-Nahhas A, et al. Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma. Biomed Pharmacother. 2008;62:139–46.PubMedCrossRef
23.
Clarke SE, Lazarus CR, Wraight P, Sampson C, Maisey MN. Pentavalent [99mTc]DMSA, [131I]MIBG, and [99mTc]MDP–an evaluation of three imaging techniques in patients with medullary carcinoma of the thyroid. J Nucl Med. 1988;29:33–8.PubMed
24.
Frank-Raue K, Bihl H, Dorr U, Buhr H, Ziegler R, Raue F. Somatostatin receptor imaging in persistent medullary thyroid carcinoma. Clin Endocrinol. 1995;42:31–7.CrossRef
25.
Kwekkeboom DJ, Reubi JC, Lamberts SW, Bruining HA, Mulder AH, Oei HY, et al. In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab. 1993;76:1413–7.PubMed
26.
Verga U, Muratori F, Di Sacco G, Banfi F, Libroia A. The role of radiopharmaceuticals MIBG and (V) DMSA in the diagnosis of medullary thyroid carcinoma. Henry Ford Hosp Med J. 1989;37:175–7.PubMed
27.
Ozkan ZG, Kuyumcu S, Uzum AK, Gecer MF, Ozel S, Aral F, et al. Comparison of 68Ga-DOTATATE PET-CT, 18F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma. Nucl Med Commun. 2015;36:242–50.PubMedCrossRef
28.
Arslan N, Ilgan S, Yuksel D, Serdengecti M, Bulakbasi N, Ugur O, et al. Comparison of In-111 octreotide and Tc-99m (V) DMSA scintigraphy in the detection of medullary thyroid tumor foci in patients with elevated levels of tumor markers after surgery. Clin Nucl Med. 2001;26:683–8.PubMedCrossRef
29.
Baudin E, Lumbroso J, Schlumberger M, Leclere J, Giammarile F, Gardet P, et al. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med. 1996;37:912–6.PubMed
30.
Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL, et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab. 2001;86:895–902.PubMedCrossRef
31.
Maiza JC, Grunenwald S, Otal P, Vezzosi D, Bennet A, Caron P. Use of 131 IMIBG therapy in MIBG-positive metastatic medullary thyroid carcinoma. Thyroid. 2012;22:654–5.PubMedCrossRef
32.
Giraudet AL, Vanel D, Leboulleux S, Auperin A, Dromain C, Chami L, et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab. 2007;92:4185–90.PubMedCrossRef
33.
Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328–54.PubMedCrossRef
34.
Bozkurt MF, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. Eur J Nucl Med Mol Imaging. 2017;44(9):1588–601.PubMedCrossRef
35.
Treglia G, Castaldi P, Villani MF, Perotti G, Filice A, Ambrosini V, et al. Comparison of different positron emission tomography tracers in patients with recurrent medullary thyroid carcinoma: our experience and a review of the literature. Recent Results Cancer Res. 2013;194:385–93.PubMedCrossRef
36.
Treglia G, Muoio B, Giovanella L, Salvatori M. The role of positron emission tomography and positron emission tomography/computed tomography in thyroid tumours: an overview. Eur Arch Otorhinolaryngol. 2013;270:1783–7.PubMedCrossRef
37.
Treglia G, Giovanella L, Rufini V. PET and PET/CT imaging in thyroid and adrenal diseases: an update. Hormones. 2013;12:327–33.PubMedCrossRef
38.
Treglia G, Rufini V, Salvatori M, Giordano A, Giovanella L. PET imaging in recurrent medullary thyroid carcinoma. Int J Mol Imaging. 2012;2012:324686.PubMedPubMedCentral
39.
Rufini V, Treglia G, Perotti G, Leccisotti L, Calcagni ML, Rubello D. Role of PET in medullary thyroid carcinoma. Minerva Endocrinol. 2008;33:67–73.PubMed
40.
Soussan M, Nataf V, Kerrou K, Grahek D, Pascal O, Talbot JN, et al. Added value of early 18F-FDOPA PET/CT acquisition time in medullary thyroid cancer. Nucl Med Commun. 2012;33(7):775–9.PubMedCrossRef
41.
Treglia G, Stefanelli A, Castaldi P, Rufini V. A standardized dual-phase 18F-DOPA PET/CT protocol in the detection of medullary thyroid cancer. Nucl Med Commun. 2013;34(2):185–6.PubMedCrossRef
42.
Chondrogiannis S, Marzola MC, Al-Nahhas A, Venkatanarayana TD, Mazza A, Opocher G, et al. Normal biodistribution pattern and physiologic variants of 18F-DOPA PET imaging. Nucl Med Commun. 2013;34(12):1141–9.PubMedPubMedCentral
43.
Chondrogiannis S, Grassetto G, Marzola MC, Rampin L, Massaro A, Bellan E, et al. 18F-DOPA PET/CT biodistribution consideration in 107 consecutive patients with neuroendocrine tumours. Nucl Med Commun. 2012;33(2):179–84.PubMedCrossRef
44.
Treglia G, Cocciolillo F, Di Nardo F, Poscia A, de Waure C, Giordano A, et al. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 dihydroxyphenylalanine positron emission tomography: a meta-analysis. Acad Radiol. 2012;19(10):1290–9.PubMedCrossRef
45.
Treglia G, Tamburello A, Giovanella L. Detection rate of somatostatin receptor PET in patients with recurrent medullary thyroid carcinoma: a systematic review and a meta-analysis. Hormones (Athens). 2017;16(4):262–72.
46.
Traub-Weidinger T, Putzer D, von Guggenberg E, Dobrozemsky G, Nilica B, Kendler D, et al. Multiparametric PET imaging in thyroid malignancy characterizing tumour heterogeneity: somatostatin receptors and glucose metabolism. Eur J Nucl Med Mol Imaging. 2015;42(13):1995–2001.PubMedCrossRef
47.
Bodet-Milin C, Faivre-Chauvet A, Carlier T, Rauscher A, Bourgeois M, Cerato E, et al. Immuno-PET using anticarcinoembryonic antigen bispecific antibody and 68Ga-labeled peptide in metastatic medullary thyroid carcinoma: clinical optimization of the Pretargeting parameters in a first-in-human trial. J Nucl Med. 2016;57(10):1505–11.PubMedCrossRef
48.
Ong SC, Schöder H, Patel SG, Tabangay-Lim IM, Doddamane I, Gönen M, et al. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med. 2007;48(4):501–7.PubMedCrossRef
49.
Werner RA, Schmid JS, Higuchi T, Javadi MS, Rowe SP, Märkl B, et al. Predictive value of FDG-PET in patients with advanced medullary thyroid carcinoma treated with vandetanib. J Nucl Med. 2018;59(5):756–61.PubMedCrossRef
50.
Romero-Lluch AR, Cuenca-Cuenca JI, Guerrero-Vázquez R, Martínez-Ortega AJ, Tirado-Hospital JL, Borrego-Dorado I, et al. Diagnostic utility of PET/CT with (18)F-DOPA and (18)F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff. Eur J Nucl Med Mol Imaging. 2017;44(12):2004–13.PubMedCrossRef
51.
Putzer D, Kroiss A, Waitz D, Gabriel M, Traub-Weidinger T, Uprimny C, et al. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide. Eur J Nucl Med Mol Imaging. 2013;40(3):364–72.PubMedCrossRef
52.
Łapińska G, Bryszewska M, Fijołek-Warszewska A, Kozłowicz-Gudzińska I, Ochman P, Sackiewicz-Słaby A. The diagnostic role of 68Ga-DOTATATE PET/CT in the detection of neuroendocrine tumours. Nucl Med Rev Cent East Eur. 2011;14(1):16–20.PubMedCrossRef
53.
Pałyga I, Kowalska A, Gąsior-Perczak D, Tarnawska-Pierścińska M, Słuszniak J, Sygut J, et al. The role of PET-CT scan with somatostatin analogue labelled with gallium-68 (68Ga-DOTA-TATE PET-CT) in diagnosing patients with disseminated medullary thyroid carcinoma (MTC). Endokrynol Pol. 2010;61(5):507–11.
54.
Golubić AT, Pasini Nemir E, Žuvić M, Mutvar A, Kusačić Kuna S, Despot M, et al. The value of 18F-DOPA PET/CT in patients with medullary thyroid carcinoma and increased calcitonin values. Nucl Med Commun. 2017;38(7):636–41.PubMedCrossRef
55.
Archier A, Heimburger C, Guerin C, Morange I, Palazzo FF, Henry JF, et al. (18)F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2016;43(6):1027–33.PubMedCrossRef
56.
Gómez-Camarero P, Ortiz-de Tena A, Borrego-Dorado I, Vázquez-Albertino RJ, Navarro-González E, Ruiz-Franco-Baux JV, et al. Evaluation of efficacy and clinical impact of 18F-FDG-PET in the diagnosis of recurrent medullary thyroid cancer with increased calcitonin and negative imaging test. Rev Esp Med Nucl Imagen Mol. 2012;31(5):261–6.CrossRef
57.
Skoura E, Rondogianni P, Alevizaki M, Tzanela M, Tsagarakis S, Piaditis G, et al. Role of [(18)F]FDG-PET/CT in the detection of occult recurrent medullary thyroid cancer. Nucl Med Commun. 2010;31(6):567–75.
58.
Rasul S, Hartenbach S, Rebhan K, Göllner A, Karanikas G, Mayerhoefer M, et al. [18F]DOPA PET/ceCT in diagnosis and staging of primary medullary thyroid carcinoma prior to surgery. EurJ Nucl Med Mol Imaging. 2018;45(12):2159–69.PubMedPubMedCentralCrossRef
59.
Treglia G, Villani MF, Giordano A, Rufini V. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis. Endocrine. 2012;42:535–45.PubMedCrossRef
60.
Kauhanen S, Schalin-Jäntti C, Seppänen M, Kajander S, Virtanen S, Schildt J, et al. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer. J Nucl Med. 2011;52(12):1855–63.PubMedCrossRef
61.
Ozkan E, Soydal C, Kucuk ON, Ibis E, Erbay G. Impact of 18F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma. Nucl Med Commun. 2011;32(12):1162–8.PubMedCrossRef
62.
Jang HW, Choi JY, Lee JI, Kim HK, Shin HW, Shin JH, et al. Localization of medullary thyroid carcinoma after surgery using (11)C-methionine PET/CT: comparison with (18)F-FDG PET/CT. Endocr J. 2010;57(12):1045–54.PubMedCrossRef
63.
Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010;16(21):5260–8.PubMedPubMedCentralCrossRef
64.
Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol. 2010;28(14):2323–30.PubMedPubMedCentralCrossRef
65.
Skoura E, Rondogianni P, Alevizaki M, Tzanela M, Tsagarakis S, Piaditis G, et al. Role of [(18)F]FDG-PET/CT in the detection of occult recurrent medullary thyroid cancer. Nucl Med Commun. 2010;31(6):567–75.
66.
Marzola MC, Pelizzo MR, Ferdeghini M, Toniato A, Massaro A, Ambrosini V, et al. Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: comparison with conventional imaging. Eur J Surg Oncol. 2010;36(4):414–21.CrossRef
67.
Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Kasperbauer JL, et al. The prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in patients with suspected residual or recurrent medullary thyroid carcinoma. Mol Imaging Biol. 2010;12(5):547–53.PubMedCrossRef
68.
Beheshti M, Pöcher S, Vali R, Waldenberger P, Broinger G, Nader M, et al. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Eur Radiol. 2009;19(6):1425–34.PubMedCrossRef
69.
Rubello D, Rampin L, Nanni C, Banti E, Ferdeghini M, Fanti S, et al. The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study. Eur J Surg Oncol. 2008;34(5):581–6.CrossRef
70.
Oudoux A, Salaun PY, Bournaud C, Campion L, Ansquer C, Rousseau C, et al. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metab. 2007;92(12):4590–7.CrossRef
71.
Ong SC, Schöder H, Patel SG, Tabangay-Lim IM, Doddamane I, Gönen M, et al. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med. 2007;48(4):501–7.PubMedCrossRef
72.
Caobelli F, Chiaravalloti A, Evangelista L, Saladini G, Schillaci O, Vadrucci M, et al. Young AIMN Working Group. Predictive and prognostic value of 18F-DOPA PET/CT in patients affected by recurrent medullary carcinoma of the thyroid. Ann Nucl Med. 2018;32(1):7–15.PubMedCrossRef
73.
Sesti A, Mayerhoefer M, Weber M, Anner P, Wadsak W, Dudczak R et al. Relevance of calcitonin cut-off in the follow-up of medullary thyroid carcinoma for conventional imaging and 18-fluorine-flurodihydroxyphenylalanine PET. Anticancer res 2014;34:6647–54.
74.
Treglia G, Aktolun C, Chiti A, Frangos S, Giovanella L, Hoffmann M, et al. EANM and the EANM thyroid committee. The 2015 revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the “evidence-based” refusal to endorse them by EANM due to the “not evidence-based” marginalization of the role of nuclear medicine. Eur J Nucl Med Mol Imaging. 2016;43(8):1486–90.PubMedCrossRef
75.
Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, et al. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid. 2010;20(5):527–33.PubMedCrossRef
76.
Soussan M, Nataf V, Kerrou K, Grahek D, Pascal O, Talbot JN, et al. Added value of early 18F-FDOPA PET/CT acquisition time in medullary thyroid cancer. Nucl Med Commun. 2012;33(7):775–9.PubMedCrossRef
77.
Yamaga LYI, Cunha ML, Campos Neto GC, Garcia MRT, Yang JH, Camacho CP, et al. (68)Ga-DOTATATE PET/CT in recurrent medullary thyroid carcinoma: a lesion-by-lesion comparison with (111)In-octreotide SPECT/CT and conventional imaging. Eur J Nucl Med Mol Imaging. 2017;44(10):1695–701.PubMedCrossRef
78.
Budiawan H, Salavati A, Kulkarni HR, Baum RP. Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90)yttrium and (177)lutetium labeled somatostatin analogs: toxicity, response and survival analysis. Am J Nucl Med Mol Imaging. 2013;4(1):39–52.
79.
Tran K, Khan S, Taghizadehasl M, Palazzo F, Frilling A, Todd JF, et al. Gallium-68 dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin. Hell J Nucl Med. 2015;18(1):19–24.
Metadata
Title
EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma
Authors
Luca Giovanella
Giorgio Treglia
Ioannis Iakovou
Jasna Mihailovic
Frederik A. Verburg
Markus Luster
Publication date
01-01-2020
Publisher
Springer Berlin Heidelberg
Keyword
Pathology
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 1/2020
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-019-04458-6

Other articles of this Issue 1/2020

European Journal of Nuclear Medicine and Molecular Imaging 1/2020 Go to the issue

Editorial

Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients

Letter to the Editor

Fitting of late dynamic [18F]MK6240 PET scans for in vivo tau quantification

Original Article

68Ga-PSMA I&T PET/CT for primary staging of prostate cancer

Image of the Month

An uncommon presentation of diffuse large B cell lymphoma with multiple peripheral nerve involvement demonstrated BY 18F-FDG PET/CT

Editorial

Performance of 18F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancer

Original Article

A combined analysis of maximum standardized uptake value on FDG-PET, genetic markers, and clinicopathological risk factors in the prognostic stratification of patients with resected oral cavity squamous cell carcinoma